Natera, Inc. (NASDAQ:NTRA) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd raised its position in Natera, Inc. (NASDAQ:NTRA) by 24.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,846 shares of the medical research company’s stock after acquiring an additional 940 shares during the quarter. XTX Topco Ltd’s holdings in Natera were worth $525,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in NTRA. Vanguard Group Inc. raised its position in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after purchasing an additional 72,848 shares in the last quarter. Farallon Capital Management LLC boosted its stake in Natera by 13.0% during the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after acquiring an additional 452,800 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Natera by 6.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock worth $259,634,000 after acquiring an additional 148,917 shares in the last quarter. Avidity Partners Management LP increased its position in shares of Natera by 23.5% in the 4th quarter. Avidity Partners Management LP now owns 1,110,000 shares of the medical research company’s stock worth $69,530,000 after purchasing an additional 211,000 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Natera by 13.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 983,312 shares of the medical research company’s stock worth $106,483,000 after purchasing an additional 119,906 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on NTRA shares. Morgan Stanley lifted their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. BTIG Research lifted their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Robert W. Baird upped their price target on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. Finally, Piper Sandler reissued an “overweight” rating and set a $150.00 target price on shares of Natera in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $120.07.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 37,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $108.10, for a total transaction of $4,053,750.00. Following the transaction, the chief executive officer now owns 213,351 shares in the company, valued at $23,063,243.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Steven Leonard Chapman sold 37,500 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the sale, the chief executive officer now owns 213,351 shares in the company, valued at $23,063,243.10. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the transaction, the insider now directly owns 284,741 shares in the company, valued at $36,324,409.37. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,921 shares of company stock worth $10,551,281. 7.60% of the stock is owned by corporate insiders.

Natera Stock Performance

Shares of NTRA stock opened at $123.08 on Wednesday. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $132.01. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The firm has a market capitalization of $15.11 billion, a price-to-earnings ratio of -39.45 and a beta of 1.53. The business has a 50 day simple moving average of $114.84 and a 200 day simple moving average of $106.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.97) earnings per share. On average, equities research analysts anticipate that Natera, Inc. will post -1.96 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.